## Clinical Context The clinical presentation (purulent urethral discharge, dysuria) and Gram stain findings (intracellular gram-negative diplococci in PMNs) are pathognomonic for **gonorrhea** caused by *Neisseria gonorrhoeae*. ## Gram Stain Interpretation **Key Point:** Gram stain of urethral smear in males with gonorrhea has a sensitivity of ~95% and specificity of ~98%. Intracellular gram-negative diplococci ("kidney bean" or "coffee bean" morphology) within PMNs are diagnostic. **Mnemonic:** **NGGD** — *Neisseria gonorrhoeae* = Gram-negative diplococci (intracellular in urethral smear from males). ## Why Immediate Empirical Treatment is Correct **High-Yield:** Gonorrhea is a reportable STI with high risk of complications (ascending infection, PID in females, epididymitis in males). Treatment should NOT be delayed pending culture results. **Clinical Pearl:** Culture is sent for confirmation and antimicrobial susceptibility testing (to guide future therapy if resistance emerges), but it does NOT delay initial treatment. The Gram stain finding is sufficient to initiate therapy in symptomatic patients. ## Current Recommended Regimen (WHO/CDC/India Guidelines) | Regimen Component | Dose | Route | Rationale | | --- | --- | --- | --- | | **Ceftriaxone** | 500 mg | IM, single dose | First-line; covers resistant strains | | **Azithromycin** | 1 g | Oral, single dose | Covers *Chlamydia trachomatis* (co-infection in ~30% of cases) | | **Culture & Sensitivity** | — | Urethral swab | For confirmation and resistance surveillance | **Note:** Penicillin is no longer recommended due to widespread resistance in *N. gonorrhoeae*. [cite:Park 26e Ch 7; WHO STI Guidelines 2016]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.